pmc logo image
Logo of cmajCMAJ Information for AuthorsCMAJ Home Page
Journal List > CMAJ > v.142(11); Jun 1, 1990

Formats:
CMAJ. 1990 June 1; 142(11): 1209–1212.
PMCID: PMC1452577
Copyright notice
Ceftizoxime: a third-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (759K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 1209
1209
icon of scanned page 1210
1210
icon of scanned page 1211
1211
icon of scanned page 1212
1212
 
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Thompson RL. Cephalosporin, carbapenem, and monobactam antibiotics. Mayo Clin Proc. 1987 Sep;62(9):821–834. [PubMed]
  • Sanders CC, Sanders WE., Jr Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics. J Infect Dis. 1986 Nov;154(5):792–800. [PubMed]
  • Richards DM, Heel RC. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Apr;29(4):281–329. [PubMed]
  • Neu HC. Factors that affect the in-vitro activity of cephalosporin antibiotics. J Antimicrob Chemother. 1982 Nov;10 Suppl NaN:11–23. [PubMed]
  • Fu KP, Neu HC. Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother. 1980 Apr;17(4):583–590. [PubMed]
  • Barry AL, Jones RN, Thornsberry C, Fuchs PC, Gerlach EH, Sommers HM. Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition. J Antimicrob Chemother. 1982 Nov;10 Suppl NaN:25–44. [PubMed]
  • Aldridge KE, Sanders CV, Janney A, Faro S, Marier RL. Comparison of the activities of penicillin G and new beta-lactam antibiotics against clinical isolates of Bacteroides species. Antimicrob Agents Chemother. 1984 Sep;26(3):410–413. [PubMed]
  • O'Keefe JP, Venezio FR, DiVincenzo CA, Shatzer KL. Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species. Antimicrob Agents Chemother. 1987 Dec;31(12):2002–2004. [PubMed]
  • Brown WJ. National Committee for Clinical Laboratory Standards agar dilution susceptibility testing of anaerobic gram-negative bacteria. Antimicrob Agents Chemother. 1988 Mar;32(3):385–390. [PubMed]
  • Rolfe RD, Finegold SM. Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother. 1981 Nov;20(5):600–609. [PubMed]
  • Goldstein EJ, Citron DM. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group. J Clin Microbiol. 1988 Nov;26(11):2361–2366. [PubMed]
  • Cuchural GJ, Jr, Tally FP, Jacobus NV, Aldridge K, Cleary T, Finegold SM, Hill G, Iannini P, O'Keefe JP, Pierson C, et al. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother. 1988 May;32(5):717–722. [PubMed]
  • Jones RN, Barry AL, Fuchs PC, Allen SD. Ceftizoxime and cefoxitin susceptibility testing against anaerobic bacteria: comparison of results from three NCCLS methods and quality control recommendations for the reference agar dilution procedure. Diagn Microbiol Infect Dis. 1987 Oct;8(2):87–94. [PubMed]
  • Brook I. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice. J Infect Dis. 1989 Oct;160(4):651–656. [PubMed]
  • Drulak MW, Chow AW. Comparative in vitro activity of ceftizoxime, cefoperazone, and cefoxitin against anaerobic bacteria. Antimicrob Agents Chemother. 1981 Nov;20(5):683–685. [PubMed]
  • Gerding DN, Peterson LR. Comparative tissue and extravascular fluid concentrations of ceftizoxime. J Antimicrob Chemother. 1982 Nov;10 Suppl NaN:105–116. [PubMed]
  • Overturf GD, Cable DC, Forthal DN, Shikuma C. Treatment of bacterial meningitis with ceftizoxime. Antimicrob Agents Chemother. 1984 Feb;25(2):258–262. [PubMed]
  • Cutler RE, Blair AD, Burgess ED, Parks D. Pharmacokinetics of ceftizoxime. J Antimicrob Chemother. 1982 Nov;10 Suppl NaN:91–97. [PubMed]
  • Quintiliani R, Nightingale CH. Comparative pharmacokinetics of ceftizoxime and other third-generation cephalosporins in humans. J Antimicrob Chemother. 1982 Nov;10 Suppl NaN:99–104. [PubMed]
  • Plimpton HW, Crawford ED. Ceftizoxime in the treatment of urinary tract infections. J Urol. 1982 Dec;128(6):1231–1232. [PubMed]
  • Mills J, Slutkin G, Klein D, Schecter W. Ceftizoxime compared with cefamandole for treatment of soft tissue infections. J Antimicrob Chemother. 1982 Nov;10 Suppl NaN:273–279. [PubMed]
  • Hughes CE, Johnson CC, Bamberger DM, Reinhardt JF, Peterson LR, Mulligan ME, Gerding DN, George WL, Finegold SM. Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. Clin Ther. 1987;10 Suppl A:36–49. [PubMed]
  • Apuzzio JJ, Ganesh V, Pelosi MA, Landau I, Kaminetzky HA, Kaminski Z, Louria DB. Comparative clinical evaluation of ceftizoxime with clindamycin and gentamicin and cefoxitin in the treatment of postcesarean endomyometritis. Surg Gynecol Obstet. 1985 Dec;161(6):518–522. [PubMed]
  • Segev S, Kitzes R, Rubinstein E, Pitlik S, Samra Y, Shenkman L, Weinberg M. Ceftizoxime vs. cefotaxime--a comparative randomized multicenter study. Isr J Med Sci. 1988 Aug;24(8):410–414. [PubMed]
  • Yangco BG, Baird I, Lorber B, Noble R, Bermudez R, Silverblatt F, Vasquez G. Comparative efficacy and safety of ceftizoxime, cefotaxime and latamoxef in the treatment of bacterial pneumonia in high risk patients. J Antimicrob Chemother. 1987 Feb;19(2):239–248. [PubMed]
  • Tripi M, Pavone-Macaluso M, Giammanco A, Carella G. Randomized comparative trial with ceftizoxime and cefotaxime in urinary tract infections. Int Urol Nephrol. 1985;17(3):195–202. [PubMed]
  • Montgomerie JZ, Morrow JW, Canawati HN, Gilmore DS, Jiminez EM, Malik GM. Ceftizoxime in the treatment of urinary tract infection in spinal cord injury patients: comparison with tobramycin. J Antimicrob Chemother. 1982 Nov;10 Suppl NaN:247–252. [PubMed]
  • Harding GK, Nicolle LE, Haase DA, Aoki FY, Stiver HG, Blanchard RJ, Kirkpatrick JR. Prospective, randomized, comparative trials in the therapy for intraabdominal and female genital tract infections. Rev Infect Dis. 1984 Mar–Apr;6 Suppl 1:S283–S292. [PubMed]
  • Rolston KV, Jones PG, Fainstein V, Elting L, Bodey GP. Ceftizoxime plus ticarcillin: double beta-lactam therapy for infections in cancer patients. J Antimicrob Chemother. 1987 Mar;19(3):367–371. [PubMed]
  • Shikuma CM, Cable DC, Edralin G, Overturf GD. Use of ceftizoxime in the treatment of paediatric infections. J Antimicrob Chemother. 1982 Nov;10 Suppl NaN:293–295. [PubMed]
  • Kaiser AB. Antimicrobial prophylaxis in surgery. N Engl J Med. 1986 Oct 30;315(18):1129–1138. [PubMed]
  • Guastella C. Cost savings realized from interchanging ceftizoxime for cefoxitin. Am J Hosp Pharm. 1988 Nov;45(11):2376–2377. [PubMed]
  • Kesado T, Watanabe K, Asahi Y, Isono M, Ueno K. Comparative antibacterial activities of 7 alpha-methoxy cephalosporins and 7 beta-methoxyiminoacetamido cephalosporins against Bacteroides fragilis. Antimicrob Agents Chemother. 1984 Jan;25(1):131–133. [PubMed]
Articles from CMAJ : Canadian Medical Association Journal are provided here courtesy of
Canadian Medical Association